Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
11.61 ^USD	-0.34%		-3.73%	+326.84%

May. 10	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	CI

Skye Bioscience, Inc. Announces Resignation of Bobby Rai as a Member of the Board of Directors and the Nominating and Corporate Governance Committee of the Board

February 22, 2023 at 11:18 am EST

Skye Bioscience, Inc. announced that on February 14, 2023, Bobby Rai resigned as a member of the Board of Directors of the company and the Nominating and Corporate Governance Committee of the Board. Mr. Rai's resignation as a director was to focus on other commitments and is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Latest news about Skye Bioscience, Inc.

Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	Apr. 22	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	Apr. 11	CI
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating	Mar. 14	MT
Skye Bioscience, Inc. announced that it has received $40 million in funding	Mar. 12	CI
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	Mar. 10	CI
Skye Bioscience Announces Board Changes	Mar. 04	CI
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26	CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	Feb. 11	CI
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	Jan. 28	CI
Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	Dec. 11	CI
Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Skye Bioscience, Inc. Announces Board Appointments	23-09-01	CI
Skye Bioscience, Inc. acquired Bird Rock Bio, Inc. for $15.6 million.	23-08-20	CI
Skye Bioscience, Inc. announced that it has received $12 million in funding	23-08-17	CI
Skye Bioscience, Inc. announced that it expects to receive $12 million in funding	23-08-14	CI
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Skye Bioscience, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Skye Bioscience, Inc. Announces Board Changes	23-03-27	CI
Skye Bioscience, Inc. Announces Resignation of Bobby Rai as a Member of the Board of Directors and the Nominating and Corporate Governance Committee of the Board	23-02-22	CI
Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors	23-02-16	CI
Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma	23-01-24	CI

Chart Skye Bioscience, Inc.

Duration

Period

More charts

Company Profile

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.61 USD

Average target price

22 USD

Spread / Average Target

+89.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SKYE BIOSCIENCE, INC.	+326.84%	326M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research